Differences in Treatment and Outcome of Pancreatic Adenocarcinoma Stage I and II in the EURECCA Pancreas Consortium
verfasst von:
J. V. Groen, B. G. Sibinga Mulder, E. van Eycken, Z. Valerianova, J. M. Borras, L. G. M. van der Geest, G. Capretti, A. Schlesinger-Raab, M. Primic-Zakelj, A. Ryzhov, C. J. H. van de Velde, B. A. Bonsing, E. Bastiaannet, J. S. D. Mieog
The EUropean REgistration of Cancer CAre (EURECCA) consortium aims to investigate differences in treatment and to improve cancer care through Europe. The purpose of this study was to compare neo- and adjuvant chemotherapy (ACT) and outcome after tumor resection for pancreatic adenocarcinoma stage I and II in the EURECCA Pancreas consortium.
Methods
The eight, collaborating national, regional, and single-center partners shared their anonymized dataset. Patients diagnosed in 2012–2013 who underwent tumor resection for pancreatic adenocarcinoma stage I and II were investigated with respect to treatment and survival and compared using uni- and multivariable logistic and Cox regression analyses. All comparisons were performed separately per registry type: national, regional, and single-center registries.
Results
In total, 2052 patients were included. Stage II was present in the majority of patients. The use of neo-ACT was limited in most registries (range 2.8–15.5%) and was only different between Belgium and The Netherlands after adjustment for potential confounders. The use of ACT was different between the registries (range 40.5–70.0%), even after adjustment for potential confounders. Ninety-day mortality was also different between the registries (range 0.9–13.6%). In multivariable analyses for overall survival, differences were observed between the national and regional registries. Furthermore, patients in ascending age groups and patients with stage II showed a significant worse overall survival.
Conclusions
This study provides a clear insight in clinical practice in the EURECCA Pancreas consortium. The differences observed in (neo-)ACT and outcome give us the chance to further investigate the best practices and improve outcome of pancreatic adenocarcinoma.
Pancreatic cancer (PC) is one of the few types of cancer with increasing incidence and mortality rates.1 In 2017, the number of annual deaths in the European Union due to PC will exceed the number of death due to breast cancer.2 Resection is the only chance for prolonged survival; unfortunately only 15–20% of PC patients are eligible for resection due to advanced or metastatic disease at diagnosis.3 Tumor/node/metastases (TNM) stage I and II PC are generally considered eligible for resection.4 The European Society of Medical Oncology (ESMO) guidelines, during the study period and most recent, state that patients with a borderline resectable or locally advanced tumor should be treated with neoadjuvant chemotherapy (neo-ACT) in clinical trials whenever possible and that adjuvant chemotherapy (ACT) is considered as standard of care after curative resection for PC.5,6 Recently, the ESPAC-4 trial showed a survival benefit in patients treated with adjuvant gemcitabine and capecitabine compared with gemcitabine alone.7 Despite advances in (neo)-ACT, the median survival for patients with an initial resectable tumor is only 23.3 (range 12–54) months.8
Previous studies have reported variations in incidence, mortality and survival in PC between countries.9–12 The EUropean REgistration of Cancer CAre (EURECCA) consortium, established by the European CanCer Organisation (ECCO), aims to investigate differences in treatment and to improve cancer care through Europe.13 International comparisons of (neo-)ACT and outcome in surgically treated patients with PC are sparse. Therefore, the purpose of this study was to describe and compare (neo-)ACT and outcome of patients who underwent tumor resection for resectable (TNM stage I and II) pancreatic adenocarcinoma in the EURECCA Pancreas consortium.
Anzeige
Materials and Methods
Study Design and Data Preparation
This is an observational cohort study of eight partners (registries) in the EURECCA Pancreas consortium [national: Belgium (BE), The Netherlands (NL), Slovenia (SLO), Ukraine (UA), and Bulgaria (BG); regional: Catalonia (Spain) (CAT(E)) and Munich (Germany) (MU(D); and single center: Milan (Italy) (MIL(I))] who shared their anonymized dataset. Detailed description of the registries is provided in Table S1 (Supplementary). The American Joint Committee on Cancer and International Union Against Cancer TNM 7th Edition classification were used to describe stage.4,14 In case pathology TNM variables were not informative (missing or X), clinical TNM variables were used as replacement. In case clinical TNM variables also were not informative (missing or X), pathology TNM variables were considered to be “0.” The 3rd edition of the International Classification of Disease for Oncology was used for topographical and morphological (i.e., pathologic diagnosis) coding.15 Age was categorized as < 65 years, 65–75 years, and > 75 years. Overall survival (OS) was calculated from date of surgery until date of death (event) or last follow-up (censored). Ninety-day mortality was calculated to distinguish surgery-related from disease-related death.16
Patient Selection
All patients with pancreatic tumors (included codes: C25.0–C25.9; excluded: C25.4), diagnosed in 2012–2013 (present in all registries), undergoing tumor resection, for adenocarcinoma (included codes: 8140-8380, 8500-8585; excluded: 8150-8158, 8240-8249), stage I and II were included.15 Patients with a history of other malignancies were not excluded, because PC is most often determinative for the prognosis. BG could not confirm tumor resection and was only used in descriptive statistics in Table S2 (Supplementary). SLO and UA were not included in analyses of neo-ACT, because no information was available. CAT(E) and UA were not included in analyses of ACT, because no information was available.
Statistical Analyses
Statistical analyses were performed using SPSS Inc. for Windows (version 23.0). Numerical data are reported as mean [standard deviation (SD)] and compared using the one-way ANOVA test. Categorical data are reported as absolute numbers (percentages) and compared using the Chi square test. Multivariable logistics regression analyses (adjusted for sex, age group, and stage) where performed for neo-ACT, ACT, and 90-day mortality. Kaplan–Meier curves, log-rank tests, and multivariable Cox regression analyses (adjusted for sex, age group, stage) where used to compare OS. For multivariable comparisons between registries, BE (national) and CAT(E) (regional) were used as reference groups (first in alphabetic order). For reasons of bias, comparisons were performed separately per registry type: national, regional, and single-center registries. To assess the risk of missing data bias, sensitivity analyses were conducted by adding patients with “unknown” stage to the original analyses. To assess the influence of 90-day mortality on the use of ACT, multivariable sensitivity analysis was performed with 90-day mortality as covariate. To assess the influence of use of (neo-)ACT on OS, multivariable sensitivity analysis was performed with (neo-)ACT as covariates. The original results were considered robust if the sensitivity analyses showed similar results. P < 0.05 was considered statistically significant for all analyses.
Results
Patient and Tumor Characteristics
Figure S1 (Supplementary) illustrates the inclusion of patients in this study. In total, 2052 patients diagnosed in 2012–2013 underwent tumor resection for pancreatic adenocarcinoma stage I and II were included (Table 1). Distribution of males/females was largely comparable between the registries. The mean (SD) age differed between the national registries, ranging from 57.5 (11.8) years in UA to 66.7 (10.0) years in BE, and the regional registries, 67.4 (9.6) years in CAT(E) and 69.3 (9.2) years in MU(D). In all registries, stage II patients were the majority of patients undergoing tumor resection, ranging from 78.5% (UA) to 98.2% (MIL(I)). Overall, tumors were most often (73.6%) located in “head of pancreas” and “pancreatoduodenectomy” was performed in majority (81.2%) of patients, excluding SLO who did not specify type of resection. Table S2 (Supplementary) shows characteristics of patients for BG, who could not confirm tumor resection.
Table 1
Patient and tumor characteristics
Registry
National
P value
Regional
P value
Single center
Belgium (N = 469)
The Netherlands (N = 645)
Slovenia (N = 73)
Ukraine (N = 214)
Catalonia (N = 210)
Munich (N = 331)
Milan (N = 110)
N
%
N
%
N
%
N
%
N
%
N
%
N
%
Sex
Male
256
54.6%
329
51.0%
39
53.4%
130
60.7%
0.098
116
55.2%
161
48.6%
0.135
60
54.5%
Female
213
45.4%
316
49.0%
34
46.6%
84
39.3%
94
44.8%
170
51.4%
50
45.5%
Age
Mean (SD)
66.7 (10.0)
66.0 (9.0)
65.6 (10.2)
57.5 (9.8)
< 0.001
67.4 (9.6)
69.3 (9.2)
0.020
68.3 (9.8)
Stage
I
70
14.9%
65
10.1%
6
8.2%
46
21.5%
< 0.001
20
9.5%
10
3.0%
0.001
2
1.8%
II
399
85.1%
580
89.9%
67
91.8%
168
78.5%
190
90.5%
321
97.0%
108
98.2%
Location
Head of pancreas
287
61.2%
525
81.4%
56
76.7%
145
67.8%
< 0.001
176
83.8%
252
76.1%
< 0.001
70
63.6%
Body of pancreas
25
5.3%
18
2.8%
8
11.0%
20
9.3%
27
12.9%
16
4.8%
0
0.0%
Tail of pancreas
35
7.5%
47
7.3%
6
8.2%
16
7.5%
7
3.3%
27
8.2%
0
0.0%
Other pancreas
122
26.0%
55
8.5%
3
4.1%
33
15.4%
0
0.0%
36
10.9%
401
36.4%
Type of surgery
Pancreatoduodenectomy
377
80.4%
571
88.5%
0
0.0%
149
69.6%
< 0.001
200
95.2%
240
72.5%
< 0.001
70
63.6%
Other2
92
19.6%
73
11.3%
0
0.0%
65
30.4%
10
4.8%
91
27.5%
40
36.4%
Unknown
0
0.0%
1
0.2%
733
100.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
1Includes tumours from body and tail of pancreas
2Other types of pancreatectomy (e.g., total and distal pancreatectomy or enucleation)
3Authors confirmed these patients underwent oncological resections
Anzeige
Neoadjuvant Chemotherapy
Overall, the use of neo-ACT ranged from 2.8% in NL to 15.5% in MIL(I). There were no differences between the national and regional registries (Figs. 1a, b).
Fig. 1
Neoadjuvant and adjuvant chemotherapy per registry in a neoadjuvant chemotherapy in stage I, b neoadjuvant chemotherapy in stage II, c adjuvant chemotherapy in stage I, d adjuvant chemotherapy in stage II
×
Multivariable analyses showed differences in odds ratios (OR) for the use of neo-ACT between the national registries: patients in NL were less likely to receive neo-ACT compared with BE (NL: odds ratio [OR] = 0.48, 95% confidence interval [CI] = 0.29–0.89, P = 0.020; Table 2). No other predictive factors where identified in the national, regional, or single-center registries. Sensitivity analyses with patients with unknown stage added to the multivariable analyses showed similar OR.
Table 2
Multivariable analyses of (neo-)adjuvant chemotherapy, 90-day mortality, and overall survival
Use of neoadjuvant chemotherapy
Use of adjuvant chemotherapy
Ninety-day mortality
Overall survival
Odds ratio1,2
95% confidence interval
P value
Odds ratio1,2
95% confidence interval
P value
Odds ratio3
95% confidence interval
P value
Hazard ratio1
95% confidence interval
P value
National
Registry
BE
1.00
Reference
–
1.00
Reference
–
1.00
Reference
–
1.00
Reference
–
NL
0.48
0.29–0.89
0.020
0.70
0.53–0.93
0.012
0.56
0.35–0.89
0.014
1.11
0.96–1.28
0.177
SLO
–
Not in analysis
–
0.32
0.19–0.56
< 0.001
0.59
0.20–1.71
0.329
1.23
0.94–1.62
0.139
UA
–
Not in analysis
–
–
Not in analysis
–
2.21
1.23–3.68
0.007
2.29
1.83–2.85
< 0.001
Sex
Male
1.00
Reference
–
1.00
Reference
–
1.00
Reference
–
1.00
Reference
–
Female
0.97
0.53–1.79
0.928
1.16
0.89–1.49
0.273
0.36
0.23–0.56
< 0.001
0.77
0.68–0.87
< 0.001
Age group (yr)
< 65
1.00
Reference
–
1.00
Reference
–
1.00
Reference
–
1.00
Reference
–
65–75
0.84
0.44–1.58
0.583
0.41
0.31–0.55
< 0.001
2.01
1.25–3.26
0.004
1.16
1.01–1.34
0.040
> 75
0.40
0.13–1.20
0.101
0.08
0.05–0.12
< 0.001
3.66
2.05–6.54
< 0.001
1.75
1.44–2.12
< 0.001
Stage
I
1.00
Reference
–
1.00
Reference
–
1.00
Reference
–
1.00
Reference
–
II
0.55
0.26–1.18
0.126
4.68
3.11–7.04
< 0.001
1.26
0.69–2.30
0.446
1.86
1.49–2.31
< 0.001
Regional
Registry
CAT(E)
1.00
Reference
–
–
Not in analysis
–
1.00
Reference
–
1.00
Reference
–
MU(D)
1.43
0.66–3.06
0.363
–
–
–
1.63
0.79–3.37
0.189
1.29
1.03–1.61
0.026
Sex
Male
1.00
Reference
–
1.00
Reference
–
1.00
Reference
–
1.00
Reference
–
Female
0.92
0.45–1.88
0.821
1.36
0.87–2.12
0.181
0.87
0.50–1.68
0.671
1.01
0.81–1.25
0.929
Age group (yr)
< 65
1.00
Reference
–
1.00
Reference
–
1.00
Reference
–
1.00
Reference
–
65–75
0.57
0.25–1.27
0.166
0.68
0.40–1.15
0.152
0.82
0.37–1.82
0.629
1.04
0.80–1.36
0.747
> 75
0.54
0.21–1.38
0.198
0.52
0.29–0.95
0.033
1.13
0.49–2.62
0.772
1.43
1.08–1.90
0.013
Stage
I
1.00
Reference
–
1.00
Reference
–
1.00
Reference
–
1.00
Reference
–
II
0.51
0.14–1.83
0.299
2.61
0.54–12.72
0.235
2.05
0.27–15.71
0.489
1.29
0.80–2.09
0.304
Single center
Registry
MIL(I)
–
–
–
–
–
–
–
–
–
–
–
–
Sex
Male
1.00
Reference
–
1.00
Reference
–
–
–
–
1.00
Reference
–
Female
1.10
0.38–3.16
0.859
1.04
0.40–2.72
0.936
–
–
–
0.82
0.53–1.27
0.365
Age group (yr)
< 65
1.00
Reference
–
1.00
Reference
–
–
–
–
1.00
Reference
–
65–75
0.75
0.24–2.32
0.617
0.19
0.04–0.94
0.194
–
–
–
0.99
0.59–1.66
0.965
> 75
0.30
0.06–1.56
0.151
0.04
0.01–0.19
< 0.001
–
–
–
1.62
0.92–2.85
0.094
Stage
I
1.00
Reference
–
1.00
Reference
–
–
–
–
1.00
Reference
–
II
–
–
0.999
–
–
0.999
–
–
–
–
–
0.963
BE Belgium; NL The Netherlands; SLO Slovenia; UA Ukraine; CAT(E) Catalonia (Spain); MU(D) Munchen (Germany); MIL(I) Milan (Italy)
1UA provided no data on adjuvant chemotherapy therefore excluded from analyses of national registries
2CAT(E) provided no data on adjuvant chemotherapy therefore excluded from analyses of regional registries
3Multivariable analyses in the single-center registry was not possible due to low number of events
Adjuvant Chemotherapy
Overall, the use of ACT ranged from 40.5% in MU(D) to 70.0% in MIL(I). A higher proportion of ACT in stage II versus stage I was observed in all registries (Figs. 1c, d). The proportion of patients with stage II receiving ACT varied between the national registries (P = 0.017).
Multivariable analyses showed considerable differences in OR for the use of ACT between the national registries (Table 2). Patients in NL and SLO were significantly less likely to receive ACT compared with BE (NL: OR = 0.70, 95% CI = 0.53–0.93, P = 0.012; SLO: OR = 0.32, 95% CI = 0.19–0.56, P < 0.001). Furthermore, patients in ascending age group and patients with stage I were less likely to receive ACT in the national registries. In the regional and single-center registry, patients in age group > 75 years also were less likely to receive ACT. Sensitivity analyses with patients with unknown stage added to the multivariable analyses showed similar results, except that in regional and single-center registries each ascending age group was significantly less likely to receive ACT. Sensitivity analyses with 90-day mortality as covariate in the multivariable analyses showed similar OR.
Ninety-Day Mortality
Ninety-day mortality differed between the national registries (P = 0.001; Fig. 2). UA (13.6%) and MU(D) (8.5%) had the highest 90-day mortality in the national and regional registries respectively, whereas overall MIL(I) (single-center registry) had the lowest 90-day mortality (0.9%).
Fig. 2
Ninety-day mortality rates per registry
×
Multivariable analyses showed considerable differences in OR for 90-day mortality between the national registries (Table 2). Compared with BE, patients in NL had lower 90-day mortality (OR = 0.56, 95% CI = 0.35–0.89, P = 0.014) and patients in UA (OR = 2.21, 95% CI = 1.23–3.68, P = 0.007) had higher 90-day mortality. Female and the younger age group were significant protective factors for 90-day mortality in the national registries. No predictive factors were identified in the regional registries. Multivariable analyses in the single-center registry was not possible due to a low number of events. Sensitivity analyses with patients with unknown stage added to the multivariable analyses showed similar OR.
Overall Survival
OS was significantly different in the national (P < 0.001) and regional (P = 0.005) registries (Fig. 3a, c). In multivariable analysis for OS in the national registries, UA showed a significantly different OS compared with BE (hazard ratio (HR) = 2.29, 95% CI = 1.83–2.85, P < 0.001; Table 2). Female sex was a significant protective factors for OS (HR = 0.77, 95% CI = 0.68–0.87, P < 0.001). Patients in each ascending age group (65–75 years: HR = 1.16, 95% CI = 1.01–1.34, P = 0.040; > 75 years: HR = 1.75, 95% CI = 1.44–2.12, P < 0.001) and stage II (HR = 1.86, 95% CI = 1.69–2.31, P < 0.001) showed worse OS. In the regional registries, MU(D) showed a significantly different OS compared with CAT(E) (HR = 1.29, 95% CI = 1.03–1.61, P = 0.026). Age group > 75 years was a significant factor with worse OS compared to age group < 65 years (HR = 1.43, 95% CI = 1.08–1.90, P = 0.013), whereas the age group 65–75 years was not. Also, sex and stage were not significant factors for OS. In the single-center registry, only the age group > 75 years was a borderline significant factor with worse OS compared with the age group < 65 years (HR = 1.62, 95% CI = 0.92–2.85, P = 0.094).
Fig. 3
Kaplan-Meier curves of overall survival per registry: a national registries, b regional registries, and c single-center registry
×
In addition, median (95% CI) survival of patients who received ACT was: 20.1 (18.5–21.7) months in the national-, 19.0 (15.6–22.4) months in the regional-, and 30.0 (24.4–35.6) months in the single center registries and median (95% CI) survival of ACT naïve patients: 12.1 (10.3–13.9) months in the national-, 14.0 (11.2–16.8) months in the regional-, and 19.0 (11.1–26.8) months in the single center registries, although a direct comparison is not possible.
Anzeige
Sensitivity analyses with patients with unknown stage added to the multivariable analyses showed similar HR. Sensitivity analyses with ACT added to the multivariable analyses showed similar HR.
Discussion
The main purpose of this study was to describe and compare (neo–)ACT and outcomes of patients who underwent tumor resection for stage I and II pancreatic adenocarcinoma in the EURECCA consortium. There were some differences in the use of neo-ACT. Although the ESMO guidelines—during the study period and most recently—recommended the use of ACT, variations were observed in OR for ACT usage between national registries.6 Also, large variations in 90-day mortality and OS were observed between the registries included in this study.
Previous studies from the EURECCA consortium showed variations in the use of chemo(radiation)therapy in colon, rectal, and breast cancer patients.17–19 The observed variations in neo-ACT, but mainly ACT, between the registries in this study are in concordance with a recent large-scale international study of resected PC patients.20 A possible explanation for the variations can be differences in adherence to (inter)national guidelines.18,19 Also, cultural, socioeconomic, and healthcare differences may play a role in the use of (neo-)ACT.21–23 The observation that few patients received neo-ACT was probably due to the statement by the ESMO guidelines (during the study period) that neo-ACT should be used in clinical trial settings.6 Clinical trials are more easily accessible in specialized centers, which explains the greater use of neo-ACT in the (specialized) single-center registry compared with the national and regional registries. A recent meta-analysis has shown the benefit of neo-ACT over upfront surgery.24 An interesting international comparison would be how these results are implemented in more recent practice. A complicated postoperative course can delay or omit the use of ACT.25 In a sensitivity analyses with 90-day mortality added to the multivariable analyses for the use of ACT, we confirmed that differences in 90-day mortality were not of influence on the differences in the use of ACT between the registries. The use of ACT decreased per ascending age group and patients in the age group > 75 years showed a significant worse OS in multivariable analyses in the national, regional, and single-center registries. As previously investigated, elderly patients are at higher risk of postoperative complications.26 Although centralization improved outcome of pancreatic surgery in elderly patients in a recent study, further research is needed to gain knowledge on this matter.27
Variations in 90-day mortality were observed between the national registries, even after adjustment for sex, age group, and stage. Multiple studies have shown a lower postoperative mortality after pancreatic surgery in high- compared with low-volume hospitals.28,29 In our study this could not be assessed, because the annual hospital volumes were not available. Nonetheless, BE and MU(D) showed a high 90-day mortality and centralization of pancreatic surgery was not (yet) implemented over there during the study period. Caution has to be taken with this statement as detailed information about perioperative treatment, likely to affect 90-day mortality, was not available.
Anzeige
This study showed a better survival in patients receiving ACT compared with naïve patients in the national, regional, and single-center registries. This can be explained by confounding by indication (fit patients with a good prognosis are generally more likely to receive ACT), and therefore a justifiable comparison is not possible. The recent ESPAC-4 trial (2017) showed a significant better survival for patients treated with adjuvant gemcitabine and capecitabine compared with gemcitabine alone (28.0 (95% CI = 23.5–31.5 months vs. 25.5 (95% CI = 22.7–27.9) months) after resection for PC.7 Considering the randomized ESPAC-trial has strict inclusion criteria (e.g., full recovery after surgery, creatinine clearance ≥ 50 mL/min) and our study is mainly population-based, the results are largely comparable. Still, direct comparison is hampered by the differences in study design. In a sensitivity analyses with (neo-)ACT added to the multivariable analyses for OS, we confirmed that differences in ACT were not of influence on the differences in OS between the registries. Definite conclusions cannot be drawn from this sensitivity analysis, because immortal time bias and confounding by indication cannot be ruled out.
Our study has several limitations. First, caution has to be taken with interpretation of the results as differences in (unmeasured) patient characteristics (e.g., patient selection for tumor resection) might have been of influence. Nevertheless, analyses were adjusted for important factors (sex, age group, stage) and still showed differences between the registries. Second, due to inherent differences between national, regional, and single-center registries, which also explain the observed inter-registry-type variations, analyses had to be performed separately per registry type and lowered the statistical power (e.g., multivariable analyses for 90-day mortality was not possible in the single-center registry). Third, due to missing data this study excluded some patients (e.g., unknown stage or tumor resection) and registries (e.g., SLO and UA did not provide data on neo-ACT, CAT(E), and UA did not provide data on ACT and the dataset from BG could not confirm tumor resection) from certain analyses. A possible explanation for this is that the provided datasets may originally have been established for other intentions (e.g., Cancer Registry or Clinical/Surgical Audit) and thus focused on completeness of certain (other) variables. Although most included registries are surgically driven and therefore very comparable, this probably introduced missing data bias.30 Sensitivity analyses with patients with unknown stage added to the analyses confirmed the robustness of the results of this study. Still, variables, such as stage and tumor resection, are pivotal when investigating treatment and outcome in cancer patients. Future registration should focus on completeness and uniform use of definitions as previously stated by other member of the EURECCA consortium.13,17 Nonetheless, this study is the first to describe and compare (neo-)ACT and outcome of patients undergoing tumor resection for pancreatic adenocarcinoma stage I and II in eight different European registries.
Conclusions
The results of this study give a clear insight in the clinical practice of the partners in the EURECCA Pancreas consortium. Overall, the variations illustrate the difference in implementation of universally accepted and used guidelines for treatment of pancreatic adenocarcinoma stage I and II. The differences in the use of (neo-)ACT and outcome provide us the chance to further investigate the best practices. Moreover, the EURECCA Pancreas consortium underlines the need for uniform registration as international comparisons will become increasingly important pillars of international guidelines.
Acknowledgment
The authors thank Dr. De Schutter and Mrs. Verbeeck (Belgian Cancer Registry, Brussels, Belgium), Dr. Manchon-Wals (Cancer Plan, Barcelona), and the Munich Cancer Registry for the collection of data. The authors also thank the registration team of the Netherlands Comprehensive Cancer Organisation (IKNL) for the collection of data for the Netherlands Cancer Registry as well as IKNL staff for scientific advice. Furthermore, the authors thank Prof. Zerbi (Pancreatic Surgery Unit, Department of Surgery, Humanitas University, Milan, Italy) for revising the manuscript.
Anzeige
Previous Communication
“Minimal Standards and Quality Assurance in Oncology: Focus on treatment of solid tumors,” Padova, Italy, October 2017.
Sources of Support
EURECCA was funded by the European Society of Surgical Oncology. This work was supported by the Bas Mulder Award (Grant UL2015-7665) from the Alpe d’HuZes foundation/Dutch Cancer Society.
Conflict of interest
All authors declare that they have no conflict of interest.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Mit der Zeitschrift Die Chirurgie erhalten Sie zusätzlich Online-Zugriff auf weitere 43 chirurgische Fachzeitschriften, CME-Fortbildungen, Webinare, Vorbereitungskursen zur Facharztprüfung und die digitale Enzyklopädie e.Medpedia.
Bis 30. April 2024 bestellen und im ersten Jahr nur 199 € zahlen!
Differences in Treatment and Outcome of Pancreatic Adenocarcinoma Stage I and II in the EURECCA Pancreas Consortium
verfasst von
J. V. Groen B. G. Sibinga Mulder E. van Eycken Z. Valerianova J. M. Borras L. G. M. van der Geest G. Capretti A. Schlesinger-Raab M. Primic-Zakelj A. Ryzhov C. J. H. van de Velde B. A. Bonsing E. Bastiaannet J. S. D. Mieog
Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.
Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?
Dr. med. Mihailo Andric Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.
